Bligny

Researchers are evaluating the impact of liquid biopsy technology to improve treatment for patients with metastatic cancer receiving care in community hospitals. This prospective biomarker study aims to demonstrate how analyzing circulating tumor DNA ctDNA using a large gene panel and microsatellite instability testing can help guide personalized therapy decisions. The study includes patients with various metastatic solid tumors, including castration-resistant prostate cancer and certain types of metastatic breast cancer resistant to standard therapies. Participants will have a blood sample taken at the start of their first-line treatment, which may include chemotherapy, immunotherapy, endocrine therapy, or targeted therapy. The collected plasma samples will undergo Next Generation Sequencing NGS to detect gene alterations and MSI status. Results will be reviewed by a Molecular Tumor Board MTB that includes specialists from multiple centers to discuss treatment options based on the molecular profile. During the study, researchers will monitor the proportion of patients with successful ctDNA sequencing and how often molecular profiling information guides treatment. They will also evaluate response rates, survival outcomes, and the timing between liquid biopsy and therapy initiation over a follow-up period of 72 months. Patients will be assessed for measurable disease, performance status, and compliance with study procedures, including providing informed consent. The study carefully tracks safety and effectiveness of molecular-guided therapy in a community oncology setting.